Short CommunicationOpen Access cc icon

Real-world disease burden and outcomes of brain metastases in EGFR mutation-positive non-small-cell lung cancer

Eric Nadler

Janet L Espirito

Melissa Pavilack

Bismark Baidoo

Ancilla Fernandes

Eric Nadler

*Author for correspondence:

E-mail Address: eric.nadler@usoncology.com

Texas Oncology, Dallas, TX 75246, USA

Search for more papers by this author

Janet L Espirito

McKesson Life Sciences, The Woodlands, TX 77380, USA

Search for more papers by this author

Melissa Pavilack

AstraZeneca, Gaithersburg, MD 20878, USA

Search for more papers by this author

Bismark Baidoo

McKesson Life Sciences, The Woodlands, TX 77380, USA

Search for more papers by this author

Ancilla Fernandes

AstraZeneca, Gaithersburg, MD 20878, USA

Search for more papers by this author

Published Online:4 Jun 2020https://doi.org/10.2217/fon-2020-0280

View article

Abstract

Aim: To evaluate the real-world impact of brain metastases (BM) among patients with EGFR mutation-positive (EGFRm) metastatic non-small-cell lung cancer (NSCLC). Materials & methods: This retrospective, observational matched cohort electronic health record study assessed adults with EGFRm metastatic NSCLC with/without BM. Results: Among 402 patients split equally between both cohorts (±BM), the majority were Caucasian (69%), female (65%) and with adenocarcinoma (92%). Overall symptom burden and ancillary support service use were higher and median overall survival from metastatic diagnosis was significantly shorter in BM patients (11.9 vs 16 months; p = 0.017). Conclusion: BM in EGFRm NSCLC patients can negatively impact clinical outcomes. New targeted therapies that can penetrate the blood–brain barrier should be considered for treating these patients.

Graphical abstract

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. WHO. Cancer factsheet (2018). www.who.int/news-room/fact-sheets/detail/cancer
Google Scholar
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J. Clin. 69(1), 7–34 (2019).
MedlineGoogle Scholar
3. Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small-cell lung cancer. Chest 130(4), 1211–1219 (2006).
Medline CASGoogle Scholar
4. Stanic K, Zwitter M, Hitij NT, Kern I, Sadikov A, Cufer T. Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival. Radiol. Oncol. 48(2), 173–183 (2014). • Retrospective real-world study that describes the association between EGFR mutations, frequency of brain metastases and survival.
MedlineGoogle Scholar
5. Peters S, Bexelius C, Munk V, Leighl N. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat. Rev. 45, 139–162 (2016). • Systematic review of burden of disease associated with brain metastasis from non-small-cell lung cancer.
MedlineGoogle Scholar
6. Girard N, Cozzone D, de Leotoing L et al. Extra cost of brain metastases (BM) in patients with non-squamous non-small-cell lung cancer (NSCLC): a French national hospital database analysis. ESMO Open 3(6), e000414 (2018).
MedlineGoogle Scholar
7. Fernandes AW, Wu B, Turner RM. Brain metastases in non-small-cell lung cancer patients on epidermal growth factor receptor tyrosine kinase inhibitors: symptom and economic burden. J. Med. Econ. 20(11), 1136–1147 (2017). • Burden of illnesss study in non-small-cell lung cancer patients with brain metastases treated with EGFR tyrosine kinase inhibitors.
MedlineGoogle Scholar
8. Fox BD, Cheung VJ, Patel AJ, Suki D, Rao G. Epidemiology of metastatic brain tumors. Neurosurg. Clin. N. Am. 22(1), 1–6, v (2011).
MedlineGoogle Scholar
9. Jamal-Hanjani M, Spicer J. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small-cell lung cancer metastatic to the brain. Clin. Cancer Res. 18, 938–944 (2012).
Medline CASGoogle Scholar
10. Wang BX, Ou W, Mao XY, Liu Z, Wu HQ, Wang SY. Impacts of EGFR mutation and EGFR-TKIs on incidence of brain metastases in advanced non-squamous NSCLC. Clin. Neurol. Neurosurg. 160, 96–100 (2017).
MedlineGoogle Scholar
11. Gaughan E, Costa D. Genotype-driven therapies for non-small-cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther. Adv. Med. Oncol. 3, 335–348 (2011).
Google Scholar
12. Cheng H, Xu X, Costa D, Al E. Molecular testing in lung cancer: the time is now. Curr. Oncol. Rep. 12, 335–348 (2010).
Medline CASGoogle Scholar
13. Aisner DL, Marshall CB. Molecular pathology of non-small-cell lung cancer: a practical guide. Am. J. Clin. Pathol. 138(3), 332–346 (2012).
MedlineGoogle Scholar
14. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst. 97(5), 339–346 (2005).
Medline CASGoogle Scholar
15. Rangachari D, Yamaguchi N, Vanderlaan PA et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 88(1), 108–111 (2015).
MedlineGoogle Scholar
16. Garinet S, Laurent-Puig P, Blons H, Oudart JB. Current and future molecular testing in NSCLC, what can we expect from new sequencing technologies? J. Clin. Med. 7(6), 144 (2018).
Google Scholar
17. Bhatt VR, D'Souza SP, Smith LM et al. Epidermal growth factor receptor mutational status and brain metastases in non-small-cell lung cancer. J. Glob. Oncol. 3(3), 208–217 (2016). • Large retrospective study evaluating incidence of EGFR mutations in patients with brain metastasis
MedlineGoogle Scholar
18. Colclough N, Ballard PG, Barton P et al. 64 – Preclinical comparison of the blood–brain barrier (BBB) permeability of osimertinib (AZD9291) with other irreversible next generation EGFR-TKIs. Eur. J. Cancer 69(Suppl. 1), S28 (2016).
MedlineGoogle Scholar
19. Ballard P, Yates JW, Yang Z et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models and early evidence of clinical brain metastases activity. Clin. Cancer Res. 22(20), 5130–5140 (2016).
Medline CASGoogle Scholar
20. Wu YL, Ahn MJ, Garassino MC et al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized Phase III trial (AURA3). J. Clin. Oncol. 36(26), 2702–2709 (2018).
Medline CASGoogle Scholar
21. Reungwetwattana T, Nakagawa K, Cho BC et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J. Clin. Oncol. 36(33), 3290–3297 (2018).
CASGoogle Scholar
22. Soria JC, Ohe Y, Vansteenkiste J et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378(2), 113–125 (2018).
Medline CASGoogle Scholar
23. Ramalingam SS, Vansteenkiste J, Planchard D et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med. 382(1), 41–50 (2020).
Medline CASGoogle Scholar
24. Li W, Zhao T, Xu H, Al E. The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small-cell lung cancer: a systematic review and meta-analysis. BMC Cancer 19(1), 145 (2019). •• Recent meta-analysis describing the relationship between EGFR mutation, brain metastasis and survival
MedlineGoogle Scholar
25. Park SJ, Kim HT, Lee DH et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small-cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 77(3), 556–560 (2012).
Medline CASGoogle Scholar
26. Heon S, Yeap BY, Lindeman NI et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small-cell lung cancer with EGFR mutations. Clin. Cancer Res. 18(16), 4406–4414 (2012).
Medline CASGoogle Scholar

Vol. 16, No. 22

Metrics

Downloaded 6,587 times

History

Received 31 March 2020

Accepted 15 May 2020

Published online 4 June 2020

Published in print August 2020

Information

Keywords

Author contributions

The authors were fully responsible for all content and editorial decisions, involved at all stages of manuscript development and have approved the final version.

Financial & competing interests disclosure

This study was funded by AstraZeneca, Cambridge, UK, the manufacturer of osimertinib. This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors. E Nadler reports participation in speaker bureaus for Merck, Genentech and AstraZeneca and consultancy for Merck. JL Espirito and B Baidoo are McKesson employees and shareholders. M Pavilack and A Fernandes are AstraZeneca employees and shareholders. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

The authors would like to acknowledge Charlotte Terry, of iMed Comms, Macclesfield, UK, an Ashfield Company, part of UDG Healthcare plc, for medical writing support that was funded by AstraZeneca, Cambridge, UK, in accordance with Good Publications Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

Ethical conduct of research

Institutional Review Board approval was obtained for the study.

Data sharing statement

Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Open access

This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

PDF download